# A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

> **NCT05159752** · PHASE2 · UNKNOWN · sponsor: **Clinuvel Europe Limited** · enrollment: 6 (estimated)

## Conditions studied

- Xeroderma Pigmentosum

## Interventions

- **DRUG:** Afamelanotide

## Key facts

- **NCT ID:** NCT05159752
- **Lead sponsor:** Clinuvel Europe Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-19
- **Primary completion:** 2024-03
- **Final completion:** 2024-10
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05159752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05159752, "A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05159752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*